ALS Limited (ASX:ALQ) agreed to acquire the remaining 51% stake in Nuvisan Pharma Holding Gmbh on March 25, 2024. The acquisition also includes, Nuvisan GmbH and Innovation Campus Berlin. The total acquisition price paid is attractive and timely for a European-based CRO.

As of calendar year 2023, Nuvisan Pharma reported revenues of approximately AUD 250 million. The transaction will be funded from existing liquidity and profitability improvement. The acquisition is expected to close on March 31, 2024.